Abstract
Objective:Neonatal hyperbilirubinemia is a short-lasting benign condition that affects approximately 60% of infants born at term infants. This study aimed to evaluate the effects of antenatal corticosteroid (ACS) exposure on the rate of hyperbilirubinemia in term newborns.Methods:This retrospective study was conducted at the Health Sciences University Kayseri Education and Research Hospital, Turkey from June 2017 to June 2018. A total of 6254 pregnant participants aged between 18 and 35 years with a singleton pregnancy were included in the study. The study group included 354 women with low-risk pregnancies (no perinatal risk except threatened preterm labor) who received ACS treatment and were hospitalized because of the threat of preterm labor before the 34th gestational week but delivered after 37 weeks of gestation. The control group was composed of 5900 women with low-risk pregnancies who did not receive ACS treatment throughout their pregnancy and delivered after 37 weeks of gestation.Results:Maternal age, mean body mass index, gestational week at delivery, nulliparity, previous cesarean history, sex of the baby, fetal weight, labor induction, vaginal delivery, and five minutes. Apgar score were similar in both groups. The neonatal hyperbilirubinemia rate was 20/354 (5.6%) in the ACS treatment group and 564/5900 (9.6%) in the control group.Conclusions:The neonatal hyperbilirubinemia was significantly decreased in term-born babies exposed to ACS before 34 weeks.
Highlights
Neonatal hyperbilirubinemia [physiologic jaundice] is a short-lasting benign condition that affects approximately 60% of infants born at term and 80% of preterm infants.[1]
The neonatal hyperbilirubinemia rate was significantly decreased in the antenatal corticosteroids (ACS) treatment group (p = 0.014)
The present study aimed to evaluate the effects of ACS treatment applied before 34 weeks of gestation on the rate of hyperbilirubinemia in term newborns and it was found that neonatal hyperbilirubinemia was significantly decreased in term newborns exposed to ACS before 34 weeks of gestation
Summary
Neonatal hyperbilirubinemia [physiologic (nonpathologic) jaundice] is a short-lasting benign condition that affects approximately 60% of infants born at term and 80% of preterm infants.[1]. Synthetic glucocorticoids can promote the rapid maturing of underdeveloped organs in fetuses, and have been demonstrated to be applicable to preventing or reducing the aforementioned complications.[6] In utero exposure to synthetic glucocorticoids during the critical stages of development can result in altered functioning of various organ systems, which may persist throughout life. There is no increased risk of death or chorioamnionitis associated with corticosteroid use.[7] On the other hand, it has been reported in various studies that ACSs are associated with neonatal hypoglycemia and hyperbilirubinemia.[8] Today, the effects of ACS administration on perinatal outcomes in the acute period are clearly known but the effects on fetal organ development and neonatal effects in the long-term are still unclear. The present study aimed to evaluate the effects of ACS exposure on the rate of hyperbilirubinemia in term newborns
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
